Background The potential of ursodeoxycholic acid (UDCA) in inhibiting angiotensin-
converting enzyme 2 was demonstrated. However, conflicting evidence emerged regarding …

Background: Several studies have investigated the relationship between ursodeoxycholic
acid (UDCA) and COVID-19 infection. However, complex and conflicting results have …

Ethnopharmacological relevance Yajieshaba (YJSB), approved by the Yunnan Provincial
Food and Drug Administration in 2008, are known for their anti-inflammatory, antiviral, and …

Background Biological evidence suggests ursodeoxycholic acid (UDCA)—a common
treatment of cholestatic liver disease—may prevent severe COVID-19 outcomes. We aimed …

Background Conflicting evidence exists regarding the effects of ursodeoxycholic acid
(UDCA) on coronavirus disease 2019 (COVID-19). This study investigates the association …

The nosocomial transmission of respiratory pathogens is an ongoing healthcare challenge,
with consequences for the health of vulnerable individuals. Outbreaks in hospitals can …

Biological evidence suggests ursodeoxycholic acid (UDCA)-a common treatment of
cholestatic liver disease-may prevent severe COVID-19 outcomes. With the approval of NHS …

Recent data suggest that ursodeoxycholic acid (UDCA) therapy may reduce susceptibility to
severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection and even …

Dear editor, We read with great interest the article by Hu et al. on the effect of
ursodeoxycholic acid (UDCA) on preventing severe acute respiratory syndrome coronavirus …

Dear Editor, We extend our sincere gratitude to Dr Shuo-Yan Gau and colleagues for their
interest in our study and for their insightful comments. 1 The readers have correctly …